AD Pipeline Update: LEO Pharma Reports Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe AD
LEO Pharma’s temtokibart, an investigational interleukin (IL)-22RA1 antagonist, performed well in adults with moderate-to-severe atopic dermatitis (AD), according to topline results from a Phase 2b trial.